Protalix Biotherapeutics Inc PLX:NYSE American

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 02/26/21 EST
4.88quote price arrow down-0.02 (-0.41%)
Volume
16,821
Close
4.90quote price arrow up+0.07 (+1.45%)
Volume
727,523
52 week range
2.04 - 7.02

...

Loading . . .

KEY STATS

  • Open5.00
  • Day High5.04
  • Day Low4.70
  • Prev Close4.83
  • 52 Week High7.02
  • 52 Week High Date02/10/21
  • 52 Week Low2.04
  • 52 Week Low Date03/16/20
  • Market Cap163.35M
  • Shares Out33.34M
  • 10 Day Average Volume2.41M
  • Dividend-
  • Dividend Yield-
  • Beta2.79
  • 1 Year % Change29.97

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date03/13/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Protalix Biotherapeutics Inc News

There is no recent news for this security.

Latest PLX News From Our Partners

QUOTE FINDER

Profile

MORE
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the...
Zeev Bronfeld
Chairman
Dror Bashan
President
Eyal Rubin
Chief Financial Officer
Address
2 Snunit St., Science Park, POB 455
Karmiel
2161401
Israel